Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy
To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 con...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2012/674265 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401121461764096 |
|---|---|
| author | Carlos Gonzalez-Juanatey Tomas R. Vazquez-Rodriguez Jose A. Miranda-Filloy Ines Gomez-Acebo Ana Testa Carlos Garcia-Porrua Amalia Sanchez-Andrade Javier Llorca Miguel A. González-Gay |
| author_facet | Carlos Gonzalez-Juanatey Tomas R. Vazquez-Rodriguez Jose A. Miranda-Filloy Ines Gomez-Acebo Ana Testa Carlos Garcia-Porrua Amalia Sanchez-Andrade Javier Llorca Miguel A. González-Gay |
| author_sort | Carlos Gonzalez-Juanatey |
| collection | DOAJ |
| description | To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease, were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month 12. Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ± standard deviation (SD): 6.1±3.9%; median: 5.7% at day 14, and mean ± SD: 7.4±2.8%; median: 6.9% at month 12) than those obtained at day 0 (mean: 4.5±4.0%; median: 3.6%; P=0.03 and P<0.001, resp.). Endothelium-independent vasodilatation results did not significantly change compared with those obtained at day 0. No significant differences were observed when carotid artery intima-media wall thickness values obtained at month 12 (mean ± SD: 0.69±0.21 mm) were compared with those found at day 0 (0.65±0.16 mm) (P=0.3). In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development of the subclinical atherosclerosis disease in RA. |
| format | Article |
| id | doaj-art-8a338e95db454d7b9ca562a3ed56489e |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-8a338e95db454d7b9ca562a3ed56489e2025-08-20T03:37:50ZengWileyMediators of Inflammation0962-93511466-18612012-01-01201210.1155/2012/674265674265Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional TherapyCarlos Gonzalez-Juanatey0Tomas R. Vazquez-Rodriguez1Jose A. Miranda-Filloy2Ines Gomez-Acebo3Ana Testa4Carlos Garcia-Porrua5Amalia Sanchez-Andrade6Javier Llorca7Miguel A. González-Gay8Cardiology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, SpainRheumatology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, SpainRheumatology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, SpainEpidemiology and Computational Biology Division, School of Medicine, University of Cantabria, Avenida Herrera Oria s/n, 39011 Santander, SpainCardiology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, SpainRheumatology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, SpainRheumatology Division, Hospital Universitario Lucus Augusti, c/Ulises Romero 1, 27003 Lugo, SpainEpidemiology and Computational Biology Division, School of Medicine, University of Cantabria, Avenida Herrera Oria s/n, 39011 Santander, SpainRheumatology Division, Hospital Universitario Marques de Valdecilla, Avenida de Valdecilla s/n, 39008 Santander, SpainTo determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease, were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month 12. Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ± standard deviation (SD): 6.1±3.9%; median: 5.7% at day 14, and mean ± SD: 7.4±2.8%; median: 6.9% at month 12) than those obtained at day 0 (mean: 4.5±4.0%; median: 3.6%; P=0.03 and P<0.001, resp.). Endothelium-independent vasodilatation results did not significantly change compared with those obtained at day 0. No significant differences were observed when carotid artery intima-media wall thickness values obtained at month 12 (mean ± SD: 0.69±0.21 mm) were compared with those found at day 0 (0.65±0.16 mm) (P=0.3). In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development of the subclinical atherosclerosis disease in RA.http://dx.doi.org/10.1155/2012/674265 |
| spellingShingle | Carlos Gonzalez-Juanatey Tomas R. Vazquez-Rodriguez Jose A. Miranda-Filloy Ines Gomez-Acebo Ana Testa Carlos Garcia-Porrua Amalia Sanchez-Andrade Javier Llorca Miguel A. González-Gay Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy Mediators of Inflammation |
| title | Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy |
| title_full | Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy |
| title_fullStr | Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy |
| title_full_unstemmed | Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy |
| title_short | Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy |
| title_sort | anti tnf alpha adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy |
| url | http://dx.doi.org/10.1155/2012/674265 |
| work_keys_str_mv | AT carlosgonzalezjuanatey antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT tomasrvazquezrodriguez antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT joseamirandafilloy antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT inesgomezacebo antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT anatesta antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT carlosgarciaporrua antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT amaliasanchezandrade antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT javierllorca antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy AT miguelagonzalezgay antitnfalphaadalimumabtherapyisassociatedwithpersistentimprovementofendothelialfunctionwithoutprogressionofcarotidintimamediawallthicknessinpatientswithrheumatoidarthritisrefractorytoconventionaltherapy |